Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN1202 in stable atherosclerotic cardiovascular disease
NCT02388971Phase 2Withdrawn
- Sponsor
- Takeda
- Start
- Apr 2016
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of plozalizumab in atherosclerotic cardiovascular disease (ASCVD), sponsored by Takeda. Planned start Apr 2016; status: withdrawn.
02
Drugs
plozalizumab
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT02388971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388971.